CN Mobile Logo

Search form


First-Line Erbitux Ups H&N Survival

First-Line Erbitux Ups H&N Survival

ASCO—Cetuximab (Erbitux) added to standard first-line chemotherapy with cisplatin or carboplatin plus fluorouracil (5-FU) yielded a statistically and clinically significant 35% survival advantage over these regimens without cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), reported lead investigator Jan Baptist Vermorken, MD, PhD. He presented the results of the multicenter randomized phase III European EXTREME (Erbitux in First-line Treatment of Recurrent or Metastatic Head & Neck Cancer) study at the 2007 meeting of the American Society of Clinical Oncology.

"This is the first systemic treatment in 25 years to show a survival benefit over platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck," commented Dr. Vermorken, professor of oncology at the University of Antwerp, Belgium.

Novel therapies for head and neck cancer are clearly needed, he said, as median survival typically reported for relapsed SCCHN patients on standard chemotherapy is 6 to 7 months, and median progression-free survival time is about 2 months.

Unlike in the United States, where cetuximab is approved as single-agent therapy of recurrent or metastatic SCCHN, in Europe cetuximab is only approved for the treatment of locally or regionally advanced disease, in combination with radiotherapy.

Cetuximab, an IgG1 monoclonal antibody, specifically targets the epidermal growth factor receptor (EGFR), which is highly expressed in nearly all patients with squamous cell head and neck cancer. EGFR expression is strongly prognostic of local control, disease-free survival, and overall survival in this population.

Included in the trial were patients with stage III/IV recurrent and/or metastatic SCCHN who were not candidates for local therapy. They were required to have at least one bi-dimensionally measurable lesion (by CT or MRI) and a Karnofsky Performance Status (KPS) of at least 70. No prior EGFR testing was required.

A total of 442 patients (399 men) were randomized to receive either cetuximab (250 mg/m2 weekly, following a 400 mg/m2 initial dose) plus either cisplatin (at 100 mg/m2 IV on day 1) or carboplatin (AUC 5, on day 1) plus 5-FU (at 1,000 mg/m2/d continuous infusion on days 1 to 4), every 3 weeks (n = 222), or the same chemotherapy regimen without cetuximab (n = 220), for a maximum of six chemotherapy cycles.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.